Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature
I Marech, A Vacca, A Gnoni, N Silvestris… - Tumori …, 2013 - journals.sagepub.com
Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal
growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as …
growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as …
[引用][C] Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment
H Shen, X Zhong, X Ge, J Huang… - The Clinical Respiratory …, 2010 - Wiley Online Library
Gefitinib (AstraZeneca, Newark, DE, USA) is the first targeted drug to be approved for
advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. It has …
advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. It has …
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation
K Takamochi, K Suzuki, H Sugimura, K Funai, H Mori… - Lung Cancer, 2007 - Elsevier
Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases
EV Levchenko, VM Moiseyenko, DE Matsko… - Oncology Research …, 2009 - karger.com
Background: Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal
growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib …
growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib …
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma
F Shoji, T Yano, I Yoshino, D Mori, F Yamasaki… - European Journal of …, 2008 - Elsevier
AIMS: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small
cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse …
cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse …
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib
is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene …
is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene …
The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary …
D Kawano, T Yano, F Shoji, K Ito, Y Morodomi, A Haro… - Surgery today, 2011 - Springer
Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such
as gefitinib, exhibit up to a 70% response rate against non-small cell lung cancer (NSCLC) …
as gefitinib, exhibit up to a 70% response rate against non-small cell lung cancer (NSCLC) …
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study
BACKGROUND: Patients with lung adenocarcinoma who carry epidermal growth factor
receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor …
receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor …
[HTML][HTML] Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung …
NJ Zhao, Z Sun, Y Wang, X Ning, N Jia, C Meng… - Translational …, 2014 - Elsevier
BACKGROUND: The study aimed to compare the tolerability and efficacy of gefitinib
combined with chemotherapy agents versus chemotherapy alone for the treatment of …
combined with chemotherapy agents versus chemotherapy alone for the treatment of …
[HTML][HTML] achievement of cure with gefitinib in advanced lung adenocarcinoma harboring an activating EGFR mutation: A case report
T Kuwata, K Yoneda, K Kobayashi, R Oyama… - Case Reports in …, 2017 - karger.com
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) may
achieve long-term survival in selected cases with advanced non-small cell lung cancer …
achieve long-term survival in selected cases with advanced non-small cell lung cancer …
相关搜索
- lung adenocarcinoma surgical resection
- lung adenocarcinoma gefitinib treatment
- lung adenocarcinoma egfr mutation
- surgical resection gefitinib treatment
- surgical resection egfr mutation
- surgical intervention lung carcinoma
- gefitinib treatment egfr mutation
- lung adenocarcinoma patients with recurrence
- down staging lung carcinoma
- lung adenocarcinoma effect of gefitinib
- lung adenocarcinoma survival of patients